Daniel M. Skovronsky
Affiliations: | Founder and CEO | Avid Radiopharmaceuticals, Philadelphia, PA, United States |
Website:
http://www.avidrp.com/aboutus/aboutus_management.html#danielGoogle:
"Daniel Skovronsky"Mean distance: 15.62 (cluster 24) | S | N | B | C | P |
Cross-listing: Neuropathology Tree - Chemistry Tree
Parents
Sign in to add mentor| Nicholas K. Gonatas | post-doc | Penn | ||
| (Early 1990's) | ||||
| Virginia Man-Yee Lee | post-doc | Penn | ||
| (Early 1990's) | ||||
| John Q. Trojanowski | post-doc | Penn | ||
| (Early 1990's) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sims JR, Zimmer JA, Evans CD, et al. (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. Jama |
| Dougan M, Azizad M, Mocherla B, et al. (2021) A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America |
| Dougan M, Nirula A, Azizad M, et al. (2021) Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. The New England Journal of Medicine |
| Cohen MS, Nirula A, Mulligan MJ, et al. (2021) Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. Jama |
| Mintun MA, Lo AC, Duggan Evans C, et al. (2021) Donanemab in Early Alzheimer's Disease. The New England Journal of Medicine |
| Gottlieb RL, Nirula A, Chen P, et al. (2021) Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. Jama |
| Nirula A, Shen L, Skovronsky DM. (2020) Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. The New England Journal of Medicine. 384 |
| Chen P, Nirula A, Heller B, et al. (2020) SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. The New England Journal of Medicine |
| Grundman M, Johnson KA, Lu M, et al. (2016) Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. Dementia and Geriatric Cognitive Disorders. 41: 80-92 |
| Joshi AD, Pontecorvo MJ, Skovronsky DM, et al. (2015) A semi-automated method for quantification of florbetapir F 18 PET images. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine |